Novel vaccine shows promise against early-stage breast cancer

	Tweet

A diagnosis of breast cancer has taken on a new meaning in the past 10 years, as research has produced a host of new therapies and detection techniques, significantly improving long-term survival for women who have been fighting the disease. To build on these successes, researchers are now harnessing what they have learned about treating breast cancer and applying it to possible methods of prevention to reduce the total incidence of the disease. One study presented today at the American Association for Cancer Research’s Frontiers in Cancer Prevention Research meeting in Boston looks at a specific target in the fight against breast cancer and evaluates a potential vaccine that is yielding promising results for women who are at high-risk for the disease.

Targeted immunoediting of critical pathways responsible for breast cancer development: treatment of early breast cancer using HER-2/neu pulsed dendritic cells

Multiple genetic targets have been discovered that may help fight breast cancer, including BRCA, estrogen receptors, and HER-2/neu, all of which have been known to predict the severity of disease, recurrence and overall survival. 

Developing novel therapies that target these specific genetic variances may be extremely beneficial in preventing breast cancer for many women.

In this study, researchers investigated a potential vaccine that targets HER-2/neu over-expression in early stage breast cancer, known as DCIS (ductal carcinomas in situ, or early stage cancer formation in the breast’s milk ducts). It is estimated at 50-60 percent of DCIS is directly related to HER-2/neu over-expression.

Patients with HER-2/neu overexpression were given a therapy of dendritic cells (DC, which work with the B- and T-cells to trigger immune responses) that were treated with HER-2/neu to evoke an immune response. The participants received four weekly vaccinations into normal lymph nodes in their groins and were evaluated both pre- and post-vaccination for immune response, level of HER-2/neu expression, and cell infiltrates.

The researchers found that most patients responded well to the vaccination. Nearly all patients (11 of 12) exhibited an initial immune response (shown by the presence of anti-HER-2/neu specific CD4+ T cells), and many of the patients developed protein antibodies to fight the HER-2/neu cells. Patients began to build up reserves of white blood cells following treatment and seemed to show long-term immune responses to HER-2/neu as a result of the therapy. Of the 12 study participants, six showed markedly reduced levels of HER-2/neu expression after the vaccination, and as a result, the investigators also noted an improvement in their severity of their disease.

“The results demonstrate for the first time that this DC vaccination may have significant clinical activity against certain types of breast cancer,” said Brian J. Czerniecki, M.D., of the University of Pennsylvania, and lead author of the study. “We are confident that targeted treatment with this vaccine may effectively fight not only DCIS, but may extend to prevention of breast cancer entirely.”

According to the American Cancer Society, approximately 200,000 women will be diagnosed with breast cancer in the U.S. in 2006, though thanks to new options for patients, about 20 percent, or 40,000 patients will die. Even with improved therapies, the chance of a woman having breast cancer at some time in her life is still about one in eight.

RELATED STORIES:
Dietary calcium could possibly prevent the spread of breast cancer to bone   Cell of Origin Identified for Common Type of Breast Cancer   Even Tiny Breast Tumors Can be Aggressive and May Require Maximum Therapy   Breastfeeding, other factors may affect risk of breast cancer type   Women at risk of breast cancer decline tamoxifen   Current Status of Prognostic Profiling in Breast Cancer: study   Researchers Learn How Signaling Molecule Orchestrates Breast Cancer’s Spread   Women with Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years   Social isolation worsens cancer   Women With Breast Cancer Who Consume Soy Food Have Lower Risk of Cancer Recurrence   Obesity, estrogen breakdown tied to breast cancer   Vaccine against HER2-positive breast cancer offers complete protection in lab   Ready for relapse: Molecule helps breast cancer cells to survive in the bone marrow   Women with Breast Cancer Satisfied with Preventive Mastectomies   Just a few drinks a week tied to breast cancer   Older patients can skip breast radiation - study   PET Techniques Provide More Accurate Diagnosis, Prognosis in Challenging Breast Cancer Cases   Metabolic Factors May Play a Role in Risk for Breast Cancer   Identification of 5 genes involved in the metastasis of breast tumors to the lung   Breast Ducts: A New Site for Cancer Treatment?   International Implementation of Breast Health Guidelines for Developing Countries Published by Cance   New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]